ApolloMed net revenue boosts 31 http://www.caverta.biz/caverta-online http://www.caverta.biz/caverta-online .2 percent to $5.1M for fiscal year 2012 Apollo Medical Holdings, Inc. announced financial results for its fiscal yr ended, 2012. Fiscal Year 2012 Financial Highlights: Net income increased 31.2 percent to $5.january 31 1 million for the fiscal yr ended, 2012 in comparison to $3.january 31 9 million in the fiscal year ended, 2011 Gross profit increased 68.1 percent to $978,407 for the fiscal year ended January 31, 2012 compared to $581,862 in the fiscal season ended January 31, 2011 Operating income was for the fiscal yr ended January 31, 2012 in comparison to $4,january 31 015 in the fiscal year ended, 2011 Non-GAAP Modified EBITDA increased 33.6 percent was $181,january 31 401 for the fiscal calendar year ended, 2012 compared to $135,740 in the fiscal season ended January 31, 2011 Related StoriesGlan Clwyd Hospital N Wales invest in Esaote's G-Scan MRI unit for weight-bearing scanningFirst hospital installs Ortho Vision AnalyzerLoyola Medication, Palos Community Medical center jointly start innovative telemedicine programOther Highlights: Added 3 new medical center contracts through the year, bringing final number to six Contracted with 3 wellness plans to supply inpatient care for its members at 23 hospitals Acquired Pulmonary Critical Care Management Inc.

caverta from ranbaxy

The incidence of hematologic occasions declined following dose reduction of tivantinib from 360 milligrams twice daily to 240 milligrams twice daily. All right instances are Central Daylight Time. Oral Presentation Day and time: Saturday, 2 June, 2012, 5:00 PM – 5:15 PM Abstract number: 4006 Poster title: Tivantinib versus placebo in patients with hepatocellular carcinoma who failed one systemic therapy: Outcomes of a randomized controlled stage II trial Presenter: Lorenza Rimassa, MD Area: E Hall D1 Poster Discussion Sessions Time and time: Saturday, June 2, 2012, 8:00 AM – 12:00 PM Abstract amount: 4545 Poster title: Basic safety and efficacy of MET inhibitor tivantinib coupled with sorafenib in patients with renal cell carcinoma from a stage 1 study Poster table # 24 Presenter: Igor Puzanov, MD Location: E450a Date and period: Saturday, June 2, 2012, 1:15 PM – 5:15 PM Abstract quantity: 8519 Poster title: Protection and efficacy of MET inhibitor tivantinib combined with sorafenib in sufferers with NRAS wild-type or mutant melanoma from a phase 1 study Poster board # 8 Presenter: Julie A.


Other Posts From Category "proctology":

Related Posts